Literature DB >> 15801967

Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study.

Henk Schonewille1, Anneke Brand.   

Abstract

Leucodepletion has been shown to reduce human leucocyte antigen immunization, but studies on the effect of leucodepletion on red cell alloimmunization reported discordant results. We conducted a retrospective multicentre study to determine whether prestorage filter leucodepletion alters the development of clinically significant red blood cell alloimmunization against the Rhesus, Kell, Duffy, Kidd and MSs blood group systems. Two periods were investigated, 2 years before and 2 years after universal leucodepletion. Comparisons were made between the transfused patient cohorts. To control for changes not related to leucoreduction, we compared antibody incidence with antibody prevalence in the two study periods. Newly detected antibodies (n = 4770) were found in 4115 patients from 19 participating hospitals. Of these, 857 antibodies in 659 patients were because of transfusions given in the study periods. The immunization risk was 0.13% for both periods. No differences were found regarding incidence of new antibodies, nor for patients regarding age, sex, previous antibodies, multiple antibodies, additional antibodies, number of transfusions, transfusions episodes and days from transfusion to date of immunization. In conclusion, compared with buffy-coat leucoreduction, universal prestorage filter leucodepletion did not alter the development of clinically significant red blood cell alloimmunization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801967     DOI: 10.1111/j.1365-2141.2005.05408.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

2.  Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.

Authors:  Alexis A Thompson; Melody J Cunningham; Sylvia T Singer; Ellis J Neufeld; Elliott Vichinsky; Robert Yamashita; Patricia Giardina; Hae-Young Kim; Felicia Trachtenberg; Janet L Kwiatkowski
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

Review 3.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

Review 4.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

5.  Type and screen policy in the blood bank: Is AHG cross-match still required? A study at a multispecialty corporate hospital in India.

Authors:  Sangeeta Pathak; M Chandrashekhar; G R Wankhede
Journal:  Asian J Transfus Sci       Date:  2011-07

6.  Impact of antigenic exposures and role of molecular blood grouping in enhancing transfusion safety in chronically transfused thalassemics.

Authors:  Raj Nath Makroo; Soma Agrawal; Aakanksha Bhatia; Mohit Chowdhry; Uday Kumar Thakur
Journal:  Asian J Transfus Sci       Date:  2016 Jul-Dec

7.  Comparative study of alloimmunization against red cell antigens in sickle cell disease & thalassaemia major patients on regular red cell transfusion.

Authors:  Keyuri Jariwala; Kanchan Mishra; Kanjaksha Ghosh
Journal:  Indian J Med Res       Date:  2019-01       Impact factor: 2.375

8.  A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients.

Authors:  Amal El-Beshlawy; Alshymaa Ahmed Salama; Mohamed Roshdy El-Masry; Noha M El Husseiny; Asmaa M Abdelhameed
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.